Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial.
Niemeyer-van der Kolk T, van der Wall H, Hogendoorn GK, Rijneveld R, Luijten S, van Alewijk DCJG, van den Munckhof EHA, de Kam ML, Feiss GL, Prens EP, Burggraaf J, Rissmann R, van Doorn MBA. Niemeyer-van der Kolk T, et al. Among authors: van doorn mba, van alewijk dcjg, van den munckhof eha, van der wall h. Clin Transl Sci. 2020 Sep;13(5):994-1003. doi: 10.1111/cts.12792. Epub 2020 May 1. Clin Transl Sci. 2020. PMID: 32315497 Free PMC article. Clinical Trial.
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial.
Niemeyer-van der Kolk T, Buters TP, Krouwels L, Boltjes J, de Kam ML, van der Wall H, van Alewijk DCJG, van den Munckhof EHA, Becker MJ, Feiss G, Florencia EF, Prens EP, Moerland M, Burggraaf J, Rissmann R, van Doorn MBA. Niemeyer-van der Kolk T, et al. Among authors: van doorn mba, van alewijk dcjg, van den munckhof eha, van der wall h. J Am Acad Dermatol. 2022 Apr;86(4):854-862. doi: 10.1016/j.jaad.2020.08.132. Epub 2020 Oct 1. J Am Acad Dermatol. 2022. PMID: 33010325 Clinical Trial.
Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.
Rousel J, Saghari M, Pagan L, Nădăban A, Gambrah T, Theelen B, de Kam ML, Haakman J, van der Wall HEC, Feiss GL, Niemeyer-van der Kolk T, Burggraaf J, Bouwstra JA, Rissmann R, van Doorn MBA. Rousel J, et al. Among authors: van der wall hec. Int J Mol Sci. 2023 Sep 20;24(18):14315. doi: 10.3390/ijms241814315. Int J Mol Sci. 2023. PMID: 37762625 Free PMC article. Clinical Trial.
Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition.
Rousel J, Nădăban A, Saghari M, Pagan L, Zhuparris A, Theelen B, Gambrah T, van der Wall HEC, Vreeken RJ, Feiss GL, Niemeyer-van der Kolk T, Burggraaf J, van Doorn MBA, Bouwstra JA, Rissmann R. Rousel J, et al. Among authors: van der wall hec. Exp Dermatol. 2024 Jan;33(1):e14952. doi: 10.1111/exd.14952. Epub 2023 Nov 16. Exp Dermatol. 2024. PMID: 37974545
177 results